AI Signal Dashboard
Last updated: 17 hours ago
Top Undervalued
+2¢
(No)
FDA approves a psychedelic for medical use in 2026? AI analysis: • +2¢ undervalued • Live Prediction Market fair value & mispricing alerts.
Undervalued Options Insights:
In mid-April 2026, President Trump signed an executive order to accelerate the approval of medical t...
🔓 Log in to see more
Real-time High Yield Opportunities
View MoreAll
Outcomes
Market
Price
AI Fair
Value
Value
Edge
YesNo
47¢
53¢
45¢
55¢
0¢
+2¢
⚠️ Risk Warning: Live data may lag! Prices can shift instantly due to news or low liquidity. Before trading, use AI Chat for [Live Recalculate], [Check Liquidity], [Trollbox Radar], or review [Fair Value Logic] to verify.
Hedging
MNMD
CMPS
ATAI
FDA approval of any psychedelic would serve as a historic, structural catalyst for the entire psychedelic biotech sector, causing massive positive price action for specialized companies like CMPS, MNMD, and ATAI. However, the event is too niche to have any meaningful impact on broader macroeconomic indices or major asset classes.
Movers
April 25, 2026 - April 28, 2026, the price of Option_'Yes' climbed from 32.5c to 43.5c. This surge was driven by President Trump's executive order aimed at accelerating psychedelic drug approvals, followed by the FDA issuing a Commissioner's National Priority Voucher to Compass Pathways, cutting the review timeline to 1-2 months and making a 2026 approval realistically possible.